Comparative Study of Proton Pump Inhibitors versus H2 Blockers in Peptic Ulcer Disease Management
DOI:
https://doi.org/10.62497/IRABCS.130Keywords:
Peptic ulcer disease, Proton pump inhibitors, H 2 receptor antagonists, H. pylori, Ulcer healing, Symptom reliefAbstract
Introduction: Peptic ulcer disease (PUD) is one of the common GI disorders where the disorder requires good acid suppression to mitigate the symptoms and heal the mucosa. Proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RAs) are known, broadly used treatments, and their preferable clinical performances need additional research.
Objective: In order to compare the efficacy of PPIs and H2RAs in the treatment of PUD with respect to symptom relief, ulcer healing, and prevention.
Methodology: This comparative study was carried out at Hayatabad Medical Complex, Peshawar and a 12-month period was taken in this study. Out of a total of 210 patients with endoscopically confirmed PUD, patients were randomly assigned to two groups: the large control group designated (A) PPIs (n=105) and the other large group designated (B) H2RAs (n=105). Demographics, type of ulcer, presence of Helicobacter pylori, symptom scores (GSRS), healed outcomes, and recurrence were data collected. The statistical analysis was performed in SPSS version 26, and chi-square and t-tests were used. The value p < 0.05 was taken to be statistically significant.
Results: There were no differences in baseline characteristics between groups (p > 0.05). At 6 weeks, the percentage of patients with reports of symptom relief was much greater in the PPI group (mean GSRS reduction: 9.6 vs. 7.2; p < 0.001). PPIs had a higher proportion of ulcer healing (89.5% vs. 72.4%; p = 0.002). The rate of recurrence at 3 months was lower in the PPI group (4.8% vs. 16.2%; p = 0.006). Adverse effects were minimal and comparable in the study groups.
Conclusion: PPIs are much more effective than H2RAs in the treatment of PUD, providing improved symptom control, greater rates of healing, and reduced recurrence.
Downloads
References
Begg M, Tarhuni M, Fotso MN, Gonzalez NA, Sanivarapu RR, Osman U, et al. Comparing the Safety and Efficacy of Proton Pump inhibitors and Histamine-2 receptor antagonists in the management of patients with peptic Ulcer Disease: a systematic review. Cureus. 2023 Aug 29;15(8). DOI: 10.7759/cureus.44341
Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology. 2022 Dec;37(12):2217-28.doi.org/10.1111/jgh.16017
Balitska OP, Germanyuk TA, Hryhoruk YM, Ivko TI, Tomashevska YO, Koval VM, et al. Comparative characteristics of proton pump inhibitor effectiveness in the treatment of gastric ulcer and duodenal ulcer. Current Issues in Pharmacy and Medical Sciences. 2020 Jun 25;33(2):57-60.DOI: 10.2478/cipms-2020-0011
Meng X, Zhu X, Li B, Liu J, Zhao J, Wang H, et al. Efficacy and safety of proton pump inhibitors and H2 receptor antagonists in the initial non eradication treatment of duodenal ulcer: A network meta analysis. Experimental and Therapeutic Medicine. 2023 Apr 21;25(6):273.doi.org/10.3892/etm.2023.11971
He HS, Li BY, Chen QT, Song CY, Shi J, Shi B. Comparison of the use of vonoprazan and proton pump inhibitors for the treatment of peptic ulcers resulting from endoscopic submucosal dissection: a systematic review and meta-analysis. Medical science monitor: international medical journal of experimental and clinical research. 2019 Feb 13;25:1169.doi.org/10.12659/MSM.911886
Komori H, Ueyama H, Nagahara A, Akazawa Y, Takeda T, Matsumoto K, et al. A prospective randomized trial of a potassium competitive acid blocker vs proton pump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia. Journal of International Medical Research. 2019 Apr;47(4):1441-52.doi.org/10.1177/0300060519828514
Van Diepen S, Coulson T, Wang X, Opgenorth D, Zuege DJ, Harris J, et al. Efficacy and safety of proton pump inhibitors versus histamine-2 receptor blockers in the cardiac surgical population: insights from the PEPTIC trial. European Journal of Cardio-Thoracic Surgery. 2022 Aug 1;62(2):ezac124.doi.org/10.1093/ejcts/ezac124
Yao DW, Ong C, Eales NM, Sultana R, Wong JJ, Lee JH. Reassessing the use of proton pump inhibitors and histamine-2 antagonists in critically ill children: a systematic review and meta-analysis. The Journal of Pediatrics. 2021 Jan 1;228:164-76.doi.org/10.1016/j.jpeds.2020.09.011
Jiang X, Li J, Xie J, Liang Z, Wan N, Jiang J et al. Histamine2-Receptor antagonists, proton pump inhibitors, or potassium-competitive acid blockers preventing delayed bleeding after endoscopic submucosal dissection: a meta-analysis. Frontiers in Pharmacology. 2019 Sep 19;10:1055.doi.org/10.3389/fphar.2019.01055
Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One. 2019 May 8;14(5):e0216750.doi.org/10.1371/journal.pone.0216750
Zhang J, Ge L, Hill M, Liang Y, Xie J, Cui D, et al. Standard-dose proton pump inhibitors in the initial non-eradication treatment of duodenal ulcer: systematic review, network meta-analysis, and cost-effectiveness analysis. Frontiers in Pharmacology. 2019 Jan 7;9:1512.doi.org/10.3389/fphar.2018.01512
Shehryar M, Ahmad RU, Kareem HK, Khan L, Ashraf MF, Hassan A, et al. Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review. Annals of Medicine and Surgery. 2022 Oct 1;82:104760.doi.org/10.1016/j.amsu.2022.104760
Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares J. Proton pump inhibitors versus H2‐antagonists: a meta‐analysis of their efficacy in treating bleeding peptic ulcer. Alimentary pharmacology & therapeutics. 2001 Jul 9;15(7):917-26.
Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, Van der Merwe S, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guidelines. 2010 Aug 16;2:1-5.
Archambault AP, Hunt RH, Cleator IG, Sutherland LR, Thomson AB, Williams CN, et al. Comparison of omeprazole with ranitidine for treatment of symptoms associated with gastroesophageal reflux disease and uncomplicated duodenal ulcer. Canadian Journal of Gastroenterology and Hepatology. 1996;10(3):156-62.
Mestrovic A, Bozic J, Vukojevic K, Tonkic A. Impact of different Helicobacter pylori eradication therapies on gastrointestinal symptoms. Medicina. 2021 Aug 5;57(8):803.doi.org/10.3390/medicina57080803
Park JC, Lee YC, Lee SK, Shin SK, Chung H, Park JJ, et al. Comparison of the efficacy of Polaprezinc plus proton pump inhibitor and rebamipide plus proton pump inhibitor treatments for endoscopic submucosal dissection-induced ulcers. Journal of Clinical Gastroenterology. 2021 Mar 1;55(3):233-8.DOI: 10.1097/MCG.0000000000001357
Zhang Y, Zhan J, Bao Q, Lu J, Tan L. Possible dementia risk of proton pump inhibitors and H2 receptor blockers use in the treatment of Helicobacter pylori: a meta-analysis study. Medical Hypotheses. 2020 Nov 1;144:109989.doi.org/10.1016/j.mehy.2020.109989
Kang H, Kim BJ, Choi G, Kim JG. Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: a systematic review with meta-analysis. Medicine. 2019 Jun 1;98(24):e15860.DOI: 10.1097/MD.0000000000015860
ANGELOVSKA B, DRAKALSKA E, MICEVA D, MAKRADULI L. Analysis of The Consumption of Drugs for The Treatment of Peptic Ulcer and Gastroesophageal Reflux Issued on Prescription in A Four-Year Period. International Journal of Pharmacy Research & Technology (IJPRT). 2021;11(2):53-6.doi.org/10.31838/ijprt/11.02.09
Park JH, Song YM, Jung JH, Han K. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study. Bone. 2020 Jun 1;135:115306.doi.org/10.1016/j.bone.2020.115306
Mori H, Suzuki H. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. Journal of neurogastroenterology and motility. 2019 Jan 1;25(1):6.doi.org/10.5056/jnm18139
Kumar V, Chauhan SK. An Update On Proton-Pump Inhibitors As A Treatment Of Peptic Ulcers And Gastroesophageal Reflux Disease (Gerd). International Journal In Pharmaceutical Sciences. https://10.5281/zenodo. 2023;10060470.doi.org/10.3389/fphar.2020.00607
Yamamichi N, Shimamoto T, Takahashi Y, Takahashi M, Takeuchi C, Wada R, et al. Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan. PLoS One. 2022 Jun 17;17(6):e0270252.doi.org/10.1371/journal.pone.0270252
Zhu W, Chen L, Zhang J, Wang P. Effects of high-dose versus low-dose proton pump inhibitors for treatment of gastrointestinal ulcer bleeding: a meta-analysis of randomized controlled trials. Journal of International Medical Research. 2022 Apr;50(4):03000605211067396.doi.org/10.1177/0300060521106739

Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2025 Urooba Misbah, Hafiz Dr Shoaib Ahmad , Muhammad Salman, Rida Ahmed , Anam Qazi (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain copyright to their work published in the IRABCS journal under the Creative Commons Attribution Non-Commercial No Derivatives License (CC BY-NC-ND 4.0).